Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT02652715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma
Study identification
- NCT ID
- NCT02652715
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 29 participants
Conditions and interventions
Conditions
- Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Adult T-Cell Leukemia/Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-Cell Lymphoma
- B Lymphoblastic Leukemia/Lymphoma
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Burkitt Leukemia
- Central Nervous System Lymphoma
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Diffuse Large B-Cell Lymphoma
- Enteropathy-Associated T-Cell Lymphoma
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3 Follicular Lymphoma
- Hepatosplenic T-Cell Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle Cell Lymphoma
- Mediastinal (Thymic) Large B-Cell Lymphoma
- Mycosis Fungoides
- Nasal Type Extranodal NK/T-Cell Lymphoma
- Nodal Marginal Zone Lymphoma
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Post-Transplant Lymphoproliferative Disorder
- Primary Cutaneous Anaplastic Large Cell Lymphoma
- Primary Effusion Lymphoma
- Sezary Syndrome
- Splenic Marginal Zone Lymphoma
- Subcutaneous Panniculitis-Like T-Cell Lymphoma
- Systemic Anaplastic Large Cell Lymphoma
- T Lymphoblastic Leukemia/Lymphoma
- Transformed Recurrent Non-Hodgkin Lymphoma
Interventions
- Laboratory Biomarker Analysis Other
- Quality-of-Life Assessment Other
- Questionnaire Administration Other
- Salvia hispanica Seed Dietary Supplement
Other · Dietary Supplement
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 18, 2016
- Primary completion
- Dec 20, 2018
- Completion
- Nov 11, 2019
- Last update posted
- Nov 14, 2019
2016 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02652715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2019 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02652715 live on ClinicalTrials.gov.